Australia is eagerly awaiting the introduction of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, demonstrates significant performance in clinical trials, https://thejillist.com/story12424468/this-new-drug-retatrutide-australia-a-potential-solution-for-obesity-treatment